DossierENTITY

Reblozyl

Coverage of Reblozyl in the Nexus archive.

Earliest in view: Jul 30 · 12:20 UTCMost recent: Jul 30 · 12:20 UTC

Co-mentioned in this coverage

Recent coverage

BUSINESSJul 30 · 12:20 UTCQUARTZ
Bristol Myers Squibb is raising its full-year outlook after blood thinner sales surged past expectations
Bristol Myers Squibb is raising its full-year outlook after blood thinner sales exceeded expectations. Strong sales of Eliquis, Camzyos, and Reblozyl pushed second-quarter revenue to $12.97 billion, surpassing analyst estimates.